Seaport Therapeutics (NASDAQ:SPTX) Shares Down 6% – Should You Sell?

Posted by Francis Steltz on Oct 8th, 2026

Seaport Therapeutics, Inc. (NASDAQ:SPTX – Get Free Report)’s share price fell 6% during mid-day trading on Tuesday. The company traded as low as $17.39 and last traded at $17.39. Approximately 25,821 shares traded hands during trading, a decline of 88% from the average session volume of 223,942 shares. The stock had previously closed at $18.50.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SPTX shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Seaport Therapeutics in a research report on Thursday. Raymond James Financial initiated coverage on shares of Seaport Therapeutics in a report on Friday, September 25th. They issued a “strong-buy” rating and a $46.00 price objective on the stock. JonesTrading began coverage on Seaport Therapeutics in a research report on Wednesday, August 26th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings downgraded Seaport Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Finally, Seaport Research Partners set a $46.00 target price on shares of Seaport Therapeutics in a report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Seaport Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.57.

View Our Latest Report on Seaport Therapeutics

Seaport Therapeutics Trading Up 3.2%

The business has a fifty day moving average of $22.54. The company has a market cap of $959.79 million and a P/E ratio of -1.48.

Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07). On average, equities analysts expect that Seaport Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Seaport Therapeutics

Large investors have recently bought and sold shares of the business. TRV GP VI LLC bought a new stake in shares of Seaport Therapeutics during the second quarter worth $44,769,742. Braidwell LP bought a new stake in Seaport Therapeutics during the 2nd quarter valued at about $10,860,000. Citadel Advisors LLC purchased a new stake in Seaport Therapeutics in the 2nd quarter valued at about $4,152,000. The Manufacturers Life Insurance Company bought a new position in Seaport Therapeutics in the 2nd quarter worth about $1,793,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Seaport Therapeutics during the second quarter worth approximately $1,629,000.

Seaport Therapeutics Company Profile

(Get Free Report)

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric and neurological disorders. The company’s research emphasizes therapies that modulate the brain’s GABAergic system, which plays an important role in mood, anxiety, and other central nervous system functions.

Seaport’s drug-development programs are based on its Glyph platform, a technology designed to improve the delivery of small-molecule medicines to the brain and enable oral versions of therapies that may otherwise require intravenous or other forms of administration.